Patent intelligence · US
US 9345780
Site specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
Site specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
Patent details — US 9345780
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 24, 2016
- Expiration
- May 19, 2036
- Applicant
- Tekmira Pharmaceuticals Corporation
- Claims
- 10
- CPC classes
- A61K, A61K47/545, A61K47/549, A61K47/551
Quick answer
US 9345780 (Site specific delivery of nucleic acids by combining targeting ligands with endosomolytic components) is held by Tekmira Pharmaceuticals Corporation. Status: granted. Granted May 24, 2016. Expires May 19, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Tekmira Pharmaceuticals Corporation
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K47/545, A61K47/549, A61K47/551, A61K47/554, A61K48/0008
More from Tekmira Pharmaceuticals Corporation
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 9345780?
US 9345780 (Site specific delivery of nucleic acids by combining targeting ligands with endosomolytic components) is held by Tekmira Pharmaceuticals Corporation. Status: granted. Granted May 24, 2016. Expires May 19, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9345780?
Tekmira Pharmaceuticals Corporation is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 9345780 expire?
Our index shows an expiration date of May 19, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.